Clinical Trials Logo

Adenocarcinoma clinical trials

View clinical trials related to Adenocarcinoma.

Filter by:

NCT ID: NCT02270606 Completed - Clinical trials for Recurrent Rectal Cancer

Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer

Start date: December 4, 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of fluorouracil when given together with radiation therapy followed by combination chemotherapy before and after surgery in treating patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving additional combination chemotherapy after surgery may kill any remaining tumor cells. Giving radiation therapy and fluorouracil followed by combination chemotherapy before and after surgery may be a better treatment for rectal cancer.

NCT ID: NCT02268175 Completed - Prostate Cancer Clinical Trials

Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate

Start date: October 2014
Phase: Phase 2
Study type: Interventional

This study is comparing the effectiveness of enzalutamide with or without abiraterone acetate for men with high-risk, localized prostate cancer.

NCT ID: NCT02258087 Recruiting - Clinical trials for Adenocarcinoma of Prostate

HDR vs LDR Brachytherapy as Monotherapy in the Treatment of Localized Prostate Cancer.

PROMOBRA
Start date: September 2014
Phase: Phase 2/Phase 3
Study type: Interventional

Investigators compare in a randomized clinical trial the results and side effects of high-dose- and low-dose-rate brachytherapy as monotherapy in the treatment of early, organ confined prostate cancer patients.

NCT ID: NCT02254746 Active, not recruiting - Clinical trials for Prostate Adenocarcinoma

A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer

Start date: September 2014
Phase: N/A
Study type: Interventional

The aim of this study is to test the safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) in localized prostate carcinoma in patients for whom the standard treatment is the irradiation of the entire prostate gland with or without seminal vesicles accompanied or not by hormonal therapy. In light of the accumulating clinical evidence favoring the use of hypo fractionation, SBRT regimen might constitute a much more convenient non-invasive and highly efficient outpatient therapy.

NCT ID: NCT02244489 Terminated - Clinical trials for Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Start date: November 5, 2014
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, and define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with capecitabine and oxaliplatin in adults with relapsed/refractory metastatic pancreatic ductal adenocarcinoma.

NCT ID: NCT02243371 Completed - Clinical trials for Previously Treated Metastatic Adenocarcinoma of the Pancreas

GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab

Start date: January 2, 2015
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to compare the overall survival (OS) of subjects with previously treated metastatic pancreatic cancer treated with cyclophosphamide (CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) to subjects treated with CY/GVAX pancreas vaccine followed by CRS-207 (Arm B).

NCT ID: NCT02241499 Completed - Clinical trials for Adenocarcinoma of the Esophagus or Esophagogastric Junction

Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.

PALAESTRA
Start date: October 2014
Phase: Phase 2
Study type: Interventional

In this trial, patients with histologically proven adenocarcinoma of the esophagus or esophagogastric junction noneligible for surgery or chemoradiation with curative intent will be included. Primary objective is to determine the rate of improvement in dysphagia after palliative short course hypofractionated radiotherapy (5 x 4 Gy) followed by chemotherapy consisting of oxaliplatin and fluorouracil. The rate of improvement of dysphagia is evaluated by a 5 graded dysphagia score, and a positive change of at least 1 score is considered to be an improvement.

NCT ID: NCT02241187 Completed - Pancreatic Cancer Clinical Trials

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

Start date: September 12, 2014
Phase: N/A
Study type: Interventional

This study has several purposes. DCE-MRI will be used to image the tumor. Safety of cetuximab given before surgery will be studied. Cetuximab delivery to the tumor will be studied. In Stage 2 of this study, the safety of cetuximab and PEGPH20 given before surgery will be studied. Also, the effects of PEGPH20 on tumors will be studied.

NCT ID: NCT02240524 Recruiting - Clinical trials for Advanced Gastric Adenocarcinoma

Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer

HIPEC
Start date: July 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to study the efficacy of hyperthermic intraperitoneal chemotherapy in the treatment of patients with locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy. It is a multicentric and randomised phase III trial.

NCT ID: NCT02239432 Recruiting - Clinical trials for Adenocarcinoma of the Lung

Telomere Biology in Early Adenocarcinoma of the Lung

Start date: September 2014
Phase: N/A
Study type: Observational

Early adenocarcinoma of the lung has an excellent five-year survival after resection. However, its clinical and radiologic presentation is highly variable. Traditional means for preoperative diagnosis such as Positron Emission Tomography (PET-CT) and trans-thoracic needle biopsy demonstrate unacceptable false positive and negative rates. Telomere biology is activated aberrantly is most lung cancers but has not been studied in early stages to the best of our knowledge. The objective of this study is to evaluate telomere length and activity with suspected early stage adenocarcinoma of the lung.